{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:40:08Z","timestamp":1782776408937,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03795-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:17:17Z","timestamp":1744197437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-jin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-qin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"2","key":"3795_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.clgc.2024.01.001","volume":"22","author":"A Soares","year":"2024","unstructured":"Soares A, Bourlon MT, Wong A, et al. Management of metastatic urothelial carcinoma in emerging markets (EM): an expert opinion. Clin Genitourin Cancer. 2024;22(2):467\u201375.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"3795_CR2","first-page":"461","volume":"33","author":"R Nahar","year":"2024","unstructured":"Nahar R, Jinnah MSA, Karim SS, et al. Expression of Cyclin D1 in urothelial carcinoma of urinary bladder and its association with tumour grade. Mymensingh Med J. 2024;33(2):461\u20135.","journal-title":"Mymensingh Med J"},{"issue":"6","key":"3795_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.21037\/tau-23-619","volume":"13","author":"H Hu","year":"2024","unstructured":"Hu H, Lai S, Ni R, et al. Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a surveillance, epidemiology and end results (SEER) study of 508 patients. Transl Androl Urol. 2024;13(6):983\u201393.","journal-title":"Transl Androl Urol"},{"key":"3795_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","volume":"1248","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 2020;1248:201\u201326.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"3795_CR5","doi-asserted-by":"publisher","first-page":"e31317","DOI":"10.1016\/j.heliyon.2024.e31317","volume":"10","author":"IA Darwish","year":"2024","unstructured":"Darwish IA, Alahmad W, Vinoth R. Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors. Heliyon. 2024;10(10):e31317.","journal-title":"Heliyon"},{"issue":"14","key":"3795_CR6","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.3390\/jcm13144072","volume":"13","author":"L Di Gianfrancesco","year":"2024","unstructured":"Di Gianfrancesco L, Montagner IM, Tormen D, et al. The feasibility and diagnostic adequacy of PD-L1 expression analysis using the cytoinclusion technique in bladder cancer: A prospective Single-Center study. J Clin Med. 2024;13(14):4072.","journal-title":"J Clin Med"},{"issue":"19","key":"3795_CR7","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.3390\/diagnostics13193119","volume":"13","author":"L Di Gianfrancesco","year":"2023","unstructured":"Di Gianfrancesco L, Crestani A, Amodeo A, et al. The role of checkpoint inhibitor expression directly on exfoliated cells from bladder cancer: A narrative review. Diagnostics (Basel). 2023;13(19):3119.","journal-title":"Diagnostics (Basel)"},{"issue":"17","key":"3795_CR8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2020-1290","volume":"17","author":"X Liu","year":"2021","unstructured":"Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol. 2021;17(17):2243\u201356.","journal-title":"Future Oncol"},{"issue":"10","key":"3795_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant Atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907\u201319.","journal-title":"Ann Oncol"},{"issue":"10415","key":"3795_CR10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835\u201347.","journal-title":"Lancet"},{"issue":"10397","key":"3795_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus Cabozantinib versus Cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185\u201395.","journal-title":"Lancet"},{"issue":"10421","key":"3795_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Gladieff L, Mart\u00ednez-Garc\u00eda J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31\u201343.","journal-title":"Lancet"},{"issue":"2","key":"3795_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","volume":"10","author":"BD Lehmann","year":"2024","unstructured":"Lehmann BD, Abramson VG, Dees EC, et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic Triple-Negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2024;10(2):193\u2013201.","journal-title":"JAMA Oncol"},{"issue":"30","key":"3795_CR14","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz JE, Pujade-Lauraine E, Oaknin A, et al. Atezolizumab combined with bevacizumab and Platinum-Based therapy for Platinum-Sensitive ovarian cancer: Placebo-Controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J Clin Oncol. 2023;41(30):4768\u201378.","journal-title":"J Clin Oncol"},{"issue":"31","key":"3795_CR15","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1200\/JCO.22.02894","volume":"41","author":"HM de Vries","year":"2023","unstructured":"de Vries HM, Rafael TS, Gil-Jimenez A, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (The PERICLES Study): A Phase II Trial. J Clin Oncol. 2023;41(31):4872\u201380.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3795_CR16","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.esmoop.2023.100884","volume":"8","author":"JR Hecht","year":"2023","unstructured":"Hecht JR, Raman SS, Chan A, et al. Phase Ib study of talimogene Laherparepvec in combination with Atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023;8(2):100884.","journal-title":"ESMO Open"},{"issue":"6","key":"3795_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","volume":"28","author":"AH Ko","year":"2023","unstructured":"Ko AH, Kim KP, Siveke JT, et al. Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform. Oncologist. 2023;28(6):553\u2013e472.","journal-title":"Oncologist"},{"issue":"4","key":"3795_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, et al. Perioperative Atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol. 2024;42(4):410\u201320.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3795_CR19","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/bloodadvances.2022008344","volume":"7","author":"A Younes","year":"2023","unstructured":"Younes A, Burke JM, Cheson BD, et al. Safety and efficacy of Atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Adv. 2023;7(8):1488\u201395.","journal-title":"Blood Adv"},{"issue":"1","key":"3795_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","volume":"25","author":"A Bamias","year":"2024","unstructured":"Bamias A, Davis ID, Galsky MD, et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 2024;25(1):46\u201361.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3795_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","volume":"25","author":"E Grande","year":"2024","unstructured":"Grande E, Arranz J\u00c1, De Santis M, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024;25(1):29\u201345.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3795_CR22","first-page":"1663","volume":"136","author":"D Qian","year":"2023","unstructured":"Qian D, Xu Y, Wu Y, et al. Assessment of the safety and efficacy of combination chemotherapy and PD-1\/PD-L1 inhibitor treatment of breast cancer: A meta-analysis. Chin Med J (Engl). 2023;136(14):1663\u201370.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3795_CR23","doi-asserted-by":"publisher","first-page":"2169531","DOI":"10.1080\/21645515.2023.2169531","volume":"19","author":"Y Lu","year":"2023","unstructured":"Lu Y, Zhang X, Ning J, et al. Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. Hum Vaccin Immunother. 2023;19(1):2169531.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3795_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;84(1):49\u201364.","journal-title":"Eur Urol"},{"issue":"11","key":"3795_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14737140.2023.2265572","volume":"23","author":"C Piombino","year":"2023","unstructured":"Piombino C, Tonni E, Oltrecolli M, et al. Immunotherapy in urothelial cancer: current status and future directions. Expert Rev Anticancer Ther. 2023;23(11):1141\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"3795_CR26","doi-asserted-by":"publisher","first-page":"101393","DOI":"10.1016\/j.xcrm.2024.101393","volume":"5","author":"MD Galsky","year":"2024","unstructured":"Galsky MD, Guan X, Rishipathak D, et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus Atezolizumab in urothelial cancer. Cell Rep Med. 2024;5(2):101393.","journal-title":"Cell Rep Med"},{"issue":"3","key":"3795_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12094-023-03288-1","volume":"26","author":"M Sotelo","year":"2024","unstructured":"Sotelo M, Mu\u00f1oz-Unceta N, Matorras A, et al. Outcomes with Atezolizumab in metastatic urothelial cancer: real-world data from a single institution. Clin Transl Oncol. 2024;26(3):682\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"17","key":"3795_CR28","doi-asserted-by":"publisher","first-page":"16191","DOI":"10.1007\/s00432-023-05342-5","volume":"149","author":"J Liu","year":"2023","unstructured":"Liu J, Yang L, Wei S, et al. Efficacy and safety of Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023;149(17):16191\u2013201.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"3795_CR29","first-page":"128","volume":"29","author":"Y Fu","year":"2023","unstructured":"Fu Y, Xue G. Meta-Analysis of Atezolizumab vs docetaxel in Non-Small cell lung cancer treatment outcomes. Altern Ther Health Med. 2023;29(6):128\u201333.","journal-title":"Altern Ther Health Med"},{"issue":"12","key":"3795_CR30","doi-asserted-by":"publisher","first-page":"103972","DOI":"10.1016\/j.esmoop.2024.103972","volume":"9","author":"JE Rosenberg","year":"2024","unstructured":"Rosenberg JE, Galsky MD, Powles T, et al. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open. 2024;9(12):103972.","journal-title":"ESMO Open"},{"key":"3795_CR31","doi-asserted-by":"publisher","first-page":"101732","DOI":"10.1016\/j.toxrep.2024.101732","volume":"13","author":"A Mavadia","year":"2024","unstructured":"Mavadia A, Choi S, Ismail A, et al. An overview of immune checkpoint inhibitor toxicities in bladder cancer. Toxicol Rep. 2024;13:101732.","journal-title":"Toxicol Rep"},{"key":"3795_CR32","doi-asserted-by":"publisher","first-page":"1387198","DOI":"10.3389\/fcell.2024.1387198","volume":"12","author":"Y Xu","year":"2024","unstructured":"Xu Y, Miller CP, Tykodi SS, et al. Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors. Front Cell Dev Biol. 2024;12:1387198.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"3795_CR33","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/cancers15082311","volume":"15","author":"M Morita","year":"2023","unstructured":"Morita M, Nishida N, Aoki T, et al. Role of \u03b2-Catenin activation in the tumor immune microenvironment and immunotherapy of hepatocellular carcinoma. Cancers (Basel). 2023;15(8):2311.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3795_CR34","first-page":"12307","volume":"96","author":"E Bosnali","year":"2024","unstructured":"Bosnali E, Akdas EM, Telli E, et al. The role of immunotherapy in urological cancers. Arch Ital Urol Androl. 2024;96(2):12307.","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"3795_CR35","doi-asserted-by":"publisher","first-page":"2342599","DOI":"10.1080\/15384047.2024.2342599","volume":"25","author":"ST Evans","year":"2024","unstructured":"Evans ST, Jani Y, Jansen CS, et al. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther. 2024;25(1):2342599.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3795_CR36","first-page":"e79002","volume":"17","author":"KA Alqarni","year":"2025","unstructured":"Alqarni KA. Recent advances in immunotherapy for bladder cancer treatment. Cureus. 2025;17(2):e79002.","journal-title":"Cureus"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03795-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03795-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:04:05Z","timestamp":1744239845000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03795-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3795"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03795-1","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}